The field of epigenetic/epitranscriptomic modifications has burgeoned rapidly in the past few decades; there is growing interest in how newly identified DNA/RNA-modifying enzymes can contribute to cancer progression and response to cancer treatment. In particular, there may be an exciting opportunity in targeting these factors and in doing so, potentially achieving synergistic effects with existing cancer immunotherapies to improve patient lives. For my PhD work, I am thus interested in understanding the involvement of these factors in our immune system in the context of cancer.
I received my BA (Hons) and MSci in Natural Sciences at the University of Cambridge; I specialised in biochemistry and for my master’s project, I worked on deciphering the molecular mechanisms of the epigenetic inheritance of silencing in C. elegans with Prof Eric Miska. Prior to joining the Shi lab, I worked under the mentorship of Dr Tam Wai Leong at the Agency for Science, Technology and Research (A*STAR), Singapore and A/Prof Polly Chen at the Cancer Science Institute (CSI), where I sought to understand the role of the Zα domain in ADAR1 editing. I am currently being supported by the A*STAR National Science Scholarship (NSS) for my graduate studies.